This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (35)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Prognosis/ Outcomes  • Stroke  • Alert me on articles by topic

Novel Derivation Method and Application to Thrombolytic Therapy for Acute Stroke

Jeffrey L. Saver, MD

Arch Neurol. 2004;61:1066-1070.

Background  Number needed to treat (NNT) is a useful measure of a treatment's clinical benefit or harm. However, NNT estimates for treatments for neurologic conditions have previously been generated only for dichotomized functional outcomes, which may underestimate clinically relevant treatment effects.

Objectives  To develop a method for estimating NNTs for nonbinary outcomes from parallel design clinical trials and to illustrate its application to outcomes of fibrinolytic stroke therapy across the full range of the modified Rankin Scale (mRS) of disability.

Methods  Expert generation of joint distribution outcome tables in a model population affords a novel means to derive NNTs for nonbinary end points. Using mRS distributions from the National Institute of Neurological Disorders and Stroke–Tissue Plasminogen Activator trials, 10 neurologist and emergency physician acute stroke care experts independently specified the joint distribution of outcomes in model samples of 100 patients assigned to placebo and active therapy.

Results  The average estimated NNT for 1 additional patient to have a better outcome by 1 or more grades on the mRS as a result of treatment was 3.1 (95% confidence interval, 2.6-3.6). The estimated number needed to harm was 30.1 (95% confidence interval, 25.1-36.0). Expert estimates were robust across alternative stratifications of the mRS, with the NNT for benefit on 6- and 5-rank versions of 3.3 and 3.7 and the number needed to harm of 56.6 and 100.0, respectively.

Conclusions  Expert generation of joint distribution outcome tables enables NNT estimation across a full spectrum of nonbinary outcomes. For every 100 patients with acute stroke treated with tissue plasminogen activator, approximately 32 have a better final outcome and 3 have a worse final outcome as a result of treatment.

From the Stroke Center and Department of Neurology, UCLA School of Medicine, Los Angeles, Calif.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential for quality improvement of acute stroke management in a district general hospital
McCarron et al.
Emerg. Med. J. 2008;25:270-273.
ABSTRACT | FULL TEXT  

Time Spent at Home Poststroke: "Home-Time" a Meaningful and Robust Outcome Measure for Stroke Trials
Quinn et al.
Stroke 2008;39:231-233.
ABSTRACT | FULL TEXT  

Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials
Savitz et al.
Stroke 2007;38:3205-3212.
ABSTRACT | FULL TEXT  

Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials
Saver
Stroke 2007;38:3055-3062.
ABSTRACT | FULL TEXT  

Childhood Influenza: Number Needed to Vaccinate to Prevent 1 Hospitalization or Outpatient Visit
Lewis et al.
Pediatrics 2007;120:467-472.
ABSTRACT | FULL TEXT  

Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): A Randomized, Controlled Trial
Juttler et al.
Stroke 2007;38:2518-2525.
ABSTRACT | FULL TEXT  

Hemorrhage After Thrombolytic Therapy for Stroke: The Clinically Relevant Number Needed to Harm
Saver
Stroke 2007;38:2279-2283.
ABSTRACT | FULL TEXT  

Thrombolytic Therapy for Acute Ischemic Stroke: The Likelihood of Being Helped Versus Harmed
Demaerschalk
Stroke 2007;38:2215-2216.
FULL TEXT  

Association Between Disability Measures and Healthcare Costs After Initial Treatment for Acute Stroke
Dawson et al.
Stroke 2007;38:1893-1898.
ABSTRACT | FULL TEXT  

Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era
Ginsberg
Stroke 2007;38:1967-1972.
ABSTRACT | FULL TEXT  

Clinical Impact of NXY-059 Demonstrated in the SAINT I Trial: Derivation of Number Needed to Treat for Benefit Over Entire Range of Functional Disability
Saver
Stroke 2007;38:1515-1518.
ABSTRACT | FULL TEXT  

The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis
Rha and Saver
Stroke 2007;38:967-973.
ABSTRACT | FULL TEXT  

Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical Trials: A Literature Review and Synthesis
Banks and Marotta
Stroke 2007;38:1091-1096.
ABSTRACT | FULL TEXT  

Deriving Number-Needed-to-Treat and Number-Needed-to-Harm From the Saint I Trial Results
Saver
Stroke 2007;38:257-257.
FULL TEXT  

New and emerging treatments for stroke
Dawson and Walters
Br Med Bull 2006;0:ldl011v1-16.
ABSTRACT | FULL TEXT  

Endovascular Mechanical Clot Retrieval in a Broad Ischemic Stroke Cohort
Kim et al.
Am. J. Neuroradiol. 2006;27:2048-2052.
ABSTRACT | FULL TEXT  

On the Analysis and Interpretation of Outcome Measures in Stroke Clinical Trials: Lessons From the SAINT I Study of NXY-059 for Acute Ischemic Stroke
Koziol and Feng
Stroke 2006;37:2644-2647.
ABSTRACT | FULL TEXT  

NXY-059 for Acute Ischemic Stroke: The Promise of Neuroprotection Is Finally Realized?
Fisher
Stroke 2006;37:2651-2652.
FULL TEXT  

Using Change in the National Institutes of Health Stroke Scale to Measure Treatment Effect in Acute Stroke Trials
Bruno et al.
Stroke 2006;37:920-921.
ABSTRACT | FULL TEXT  

NXY-059 for Acute Ischemic Stroke
Lees et al.
NEJM 2006;354:588-600.
ABSTRACT | FULL TEXT